抗逆转录病毒药利托那韦用于胶质母细胞瘤联合治疗的药物重定位研究
本研究探索蛋白酶抑制剂利托那韦(RTV)在胶质母细胞瘤治疗中的增敏潜力,采用来源于原发和复发胶质母细胞瘤的短期扩增临床细胞样本及常规细胞系进行体外实验,并在患者来源异种移植模型中开展体内验证。结果显示RTV单药在临床血浆峰浓度下诱导选择性抗肿瘤、细胞静止和抗迁移活性,与替莫唑胺或放疗联用具协同增强效应,异种移植模型中RTV联合替莫唑胺延长总生存。
要点
- RTV在临床血浆峰浓度下对胶质母细胞瘤细胞显示细胞静止和抗迁移活性。
- RTV与替莫唑胺或放疗联用具协同增强效应,涉及自噬和内质网应激机制。
- 异种移植模型中RTV联合替莫唑胺延长总生存,支持其作为辅助治疗候选。
核心结论
- RTV可作为胶质母细胞瘤临床辅助治疗的药物重定位候选,值得进一步探索。
研究设计与样本
- 体外使用原发和复发胶质母细胞瘤短期扩增临床细胞样本、常规细胞系及非肿瘤人神经对照。
- 体内采用患者来源异种移植模型验证RTV单药及联合疗效。
主要发现
- RTV单药在临床血浆峰浓度下诱导选择性抗肿瘤反应,并显示细胞静止和抗迁移活性。
- 替莫唑胺或放疗进一步协同增强RTV效果,机制涉及自噬和内质网应激。
- 异种移植模型中RTV联合替莫唑胺使总生存增加。
临床怎么用
- RTV有望作为胶质母细胞瘤联合治疗的增敏辅助药物,但需进一步临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The protease inhibitor ritonavir (RTV) is a clinical-stage inhibitor of the human immunodeficiency virus. In a drug repositioning approach, we here exhibit the additional potential of RTV to augment current treatment of glioblastoma, the most aggressive primary brain tumour of adulthood. METHODS: We explored the antitumour activity of RTV and mechanisms of action in a broad spectrum of short-term expanded clinical cell samples from primary and recurrent glioblastoma and in a cohort of conventional cell lines and non-tumour human neural controls in vitro. To validate RTV efficacy in monotherapeutic and in combinatorial settings, we used patient-derived xenograft models in a series of in vivo studies. RESULTS: RTV monotherapy induced a selective antineoplastic response and demonstrated cytostatic and anti-migratory activity at clinical plasma peak levels. Additional exposure to temozolomide or irradiation further enhanced the effects synergistically, fostered by mechanisms of autophagy and increased endoplasmic reticulum stress. In xenograft models, we consequently observed increasing overall survival under the combinatorial effect of RTV and temozolomide. CONCLUSIONS: Our data establish RTV as a valuable repositioning candidate for further exploration as an adjunct therapeutic in the clinical care of glioblastoma.
引用
- Rauschenbach L, Wieland A, Reinartz R, et al. Drug repositioning of antiretroviral ritonavir for combinatorial therapy in glioblastoma. Eur J Cancer. 2020. PMID: 33091717. doi:10.1016/j.ejca.2020.09.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。